Development of [
CS1 antigen
Multiple myeloma
PET imaging
[89Zr]DFO-elotuzumab
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
19
08
2020
accepted:
26
10
2020
pubmed:
13
11
2020
medline:
29
5
2021
entrez:
12
11
2020
Statut:
ppublish
Résumé
Multiple myeloma (MM) is a bone marrow malignancy that remains mostly incurable. Elotuzumab is an FDA-approved therapeutic monoclonal antibody targeted to the cell surface glycoprotein CS1, which is overexpressed in MM cells. Identifying patients who will respond to CS1-targeted treatments such as elotuzumab requires the development of a companion diagnostic to assess the presence of CS1. Here, we evaluated [ Conjugation of desferrioxamine-p-benzyl-isothiocyanate (DFO-Bz-NCS) to elotuzumab enabled zirconium-89 radiolabeling. MM.1S-CG cells were intravenously injected in NOD SCID gamma (NSG) mice. Small animal PET imaging with [ [ These data demonstrate the feasibility of [
Identifiants
pubmed: 33179150
doi: 10.1007/s00259-020-05097-y
pii: 10.1007/s00259-020-05097-y
pmc: PMC8110592
mid: NIHMS1646059
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
elotuzumab
1351PE5UGS
Zirconium
C6V6S92N3C
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1302-1311Subventions
Organisme : NIH HHS
ID : S10 OD025264
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211466
Pays : United States
Organisme : NIH HHS
ID : S10 OD020129
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA248493
Pays : United States
Organisme : NIGMS NIH HHS
ID : P41 GM103422
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA199092
Pays : United States
Organisme : NIH HHS
ID : S10 OD027042
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB021048
Pays : United States
Références
Ghai A, et al. Preclinical development of CD38-targeted [(89)Zr]Zr-DFO-daratumumab for imaging multiple myeloma. J Nucl Med. 2018;59(2):216–22.
pubmed: 29025987
pmcid: 5807532
doi: 10.2967/jnumed.117.196063
Raab MS, et al. Multiple myeloma. Lancet. 2009;374(9686):324–39.
pubmed: 19541364
doi: 10.1016/S0140-6736(09)60221-X
Malaer JD, Mathew PA. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. Am J Cancer Res. 2017;7(8):1637–41.
pubmed: 28861320
pmcid: 5574936
National Cancer Institute. Cancer stat facts: myeloma. June 11, 2020]; Available from: http://mdanderson.libanswers.com/faq/26219 .
Nishida H, Yamada T. Monoclonal antibody therapies in multiple myeloma: a challenge to develop novel targets. J Oncol. 2019;2019:6084012.
pubmed: 31781214
pmcid: 6875016
doi: 10.1155/2019/6084012
Sondergeld P, et al. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015;13(9):599–609.
pubmed: 26452191
Wang Y, et al. Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(1):55.
pubmed: 27417553
pmcid: 4946088
doi: 10.1186/s13045-016-0284-z
Hsi ED, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–84.
pubmed: 18451245
pmcid: 4433038
doi: 10.1158/1078-0432.CCR-07-4246
Kumaresan PR, et al. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002;39(1–2):1–8.
pubmed: 12213321
doi: 10.1016/S0161-5890(02)00094-9
Boles KS, Mathew PA. Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily. Immunogenetics. 2001;52(3–4):302–7.
pubmed: 11220635
doi: 10.1007/s002510000274
Bouchon A, et al. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol. 2001;167(10):5517–21.
pubmed: 11698418
doi: 10.4049/jimmunol.167.10.5517
Tai YT, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009;113(18):4309–18.
pubmed: 19196658
pmcid: 2676088
doi: 10.1182/blood-2008-10-183772
Lonial S, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.
pubmed: 26035255
doi: 10.1056/NEJMoa1505654
Zonder JA, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552–9.
pubmed: 22184404
pmcid: 4467882
doi: 10.1182/blood-2011-06-360552
Hoyos V, Borrello I. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies. Blood. 2016;128(13):1679–87.
pubmed: 27506540
doi: 10.1182/blood-2016-05-636357
Ponomarev V. Advancing immune and cell-based therapies through imaging. Mol Imaging Biol. 2017;19(3):379–84.
pubmed: 28271366
pmcid: 5406436
doi: 10.1007/s11307-017-1069-7
Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol. 2012;159(5):499–513.
pubmed: 22881361
Vij R, Fowler KJ, Shokeen M. New approaches to molecular imaging of multiple myeloma. J Nucl Med. 2016;57(1):1–4.
pubmed: 26541780
doi: 10.2967/jnumed.115.163808
Zamagni E, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95.
pubmed: 21900189
doi: 10.1182/blood-2011-06-361386
Ehlerding EB, et al. Molecular imaging of immunotherapy targets in cancer. J Nucl Med. 2016;57(10):1487–92.
pubmed: 27469363
pmcid: 5050107
doi: 10.2967/jnumed.116.177493
Borjesson PK, et al. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50(11):1828–36.
pubmed: 19837762
doi: 10.2967/jnumed.109.065862
Gaykema SB, et al. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res. 2014;20(15):3945–54.
pubmed: 25085789
doi: 10.1158/1078-0432.CCR-14-0491
Kang L, et al. ImmunoPET imaging of CD38 in murine lymphoma models using (89)Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging. 2018;45(8):1372–81.
pubmed: 29450576
pmcid: 5994170
doi: 10.1007/s00259-018-3941-3
Dong C, Liu Z, Wang F. Radioligand saturation binding for quantitative analysis of ligand-receptor interactions. Biophys Rep. 2015;1:148–55.
pubmed: 27471749
doi: 10.1007/s41048-016-0016-5
Center for Drug Evaluation and Research, Pharmacology Reviews. 2015.
Tai YT, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–37.
pubmed: 17906076
pmcid: 2515112
doi: 10.1182/blood-2007-08-107292
Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013;88(1):168–77.
pubmed: 23731618
doi: 10.1016/j.critrevonc.2013.04.003
Lonial S, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.
pubmed: 26035255
doi: 10.1056/NEJMoa1505654
Jagannath S, et al. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol. 2018;182(4):495–503.
pubmed: 29808907
pmcid: 6105456
doi: 10.1111/bjh.15384
Campbell KS, Cohen AD, Pazina T. Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody. Elotuzumab in Multiple Myeloma Front Immunol. 2018;9:2551.
Bernal M, et al. Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol. 2009;70(10):854–7.
pubmed: 19580833
doi: 10.1016/j.humimm.2009.07.004
Dosani T, et al. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J. 2015;5:e321.
pubmed: 26140429
pmcid: 4526775
doi: 10.1038/bcj.2015.49
Pages F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–39.
pubmed: 29754777
doi: 10.1016/S0140-6736(18)30789-X
Van Heertum RL, et al. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. Drug Des Devel Ther. 2015;9:5215–23.
pubmed: 26392755
pmcid: 4573073
doi: 10.2147/DDDT.S87561
Ulaner, G.A., et al., CD38-targeted immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging. Radiology, 2020: p. 192621.
Zeglis BM, Lewis JS. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. J Vis Exp. 2015;96.
O'Donoghue JA, et al. Pharmacokinetics, biodistribution, and radiation dosimetry for (89)Zr-trastuzumab in patients with esophagogastric cancer. J Nucl Med. 2018;59(1):161–6.
pubmed: 28637800
pmcid: 5750520
doi: 10.2967/jnumed.117.194555
Laforest R, et al. [(89)Zr]Trastuzumab: evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer. Mol Imaging Biol. 2016;18(6):952–9.
pubmed: 27146421
pmcid: 5096950
doi: 10.1007/s11307-016-0951-z
Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2010;12(1):33–43.
pubmed: 19924542
doi: 10.1208/s12248-009-9157-5
Terwisscha van Scheltinga, A.G., et al., Preclinical efficacy of an antibody-drug conjugate targeting mesothelin correlates with quantitative 89Zr-immunoPET. Mol Cancer Ther, 2017. 16(1): p. 134–142.
Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576–88.
pubmed: 28653357
pmcid: 5613179
doi: 10.1002/psp4.12224
Kim J, et al. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol. 2007;122(2):146–55.
pubmed: 17046328
doi: 10.1016/j.clim.2006.09.001